Physician profile

Michael M Givertz

Cardiovascular Disease · Brookline, MA

NPI 1265499560

$146,865.92

in general payments reported to CMS, 2019-2025

22 companies · $19K in 2025

The $19K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$28,430.00
Travel and Lodging$9,923.89
Food and Beverage$3,509.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $69,697.27 2019-2025 Verquvo
Edwards Lifesciences Corporation $39,000.00 2020-2025
Astrazeneca Pharmaceuticals LP $15,863.78 2019
Acorda Therapeutics, INC $10,005.15 2019
Baxter Healthcare $4,203.00 2019
Abbott Laboratories $3,905.06 2019-2025 Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems
Bayer Healthcare Pharmaceuticals INC. $1,871.55 2025
Abiomed $469.39 2019-2023 Impella
Transmedics, INC. $439.00 2023 Organ Care System
Cvrx, INC. $316.66 2023-2025 Barostim Neo System
Endotronix, INC. $294.18 2025 Cordella Pulomonary Artery Pressure Sensor
Medtronic, INC. $143.46 2024 Micra
Biotronik INC. $140.42 2019
Medtronic Vascular, INC. $126.09 2019
United Therapeutics Corporation $103.42 2021
Show all 19 companies
CompanyGeneral paymentsYearsTop products
Pfizer INC. $85.50 2023
Amgen INC. $77.77 2019-2023 Repatha
Shockwave Medical, INC $64.46 2023 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Teleflex LLC $59.76 2025

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael M Givertz

$146,865.92

in general payments reported 2019-2025

Years
2019-2025
Top company
Merck Sharp & Dohme LLC
Context
The $19K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/284792/michael-m-givertz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.